REPL
Another FDA smackdown
Replimune is back in the penalty box. The company said the FDA rejected its cancer therapy again, and the market responded like someone pulled the fire alarm — the stock cratered 64%.
Why investors should care
This isn’t just a bad headline. A fresh FDA rejection can force a biotech to rethink timelines, spending, and headcount, which is why layoffs are now on the table. For a smaller drug developer, that’s basically the business version of “we need to cut the pizza into fewer slices.”
The bigger problem
When regulators keep saying no, the value of the whole story starts to wobble. That can mean:
- more delays before any potential approval
- more cash going out while revenue stays tiny or nonexistent
- more pressure on management to protect what’s left of the balance sheet
Big picture
Biotech investors know the drill: one FDA rejection is painful, two is a thesis check. Replimune now has to prove there’s still a path forward — and the market is clearly not in a patient mood.